A new five-year collaboration between Johns Hopkins University and biopharmaceutical company Bristol-Myers Squibb aims to determine why some patients being treated for cancer respond to immunotherapy drugs called checkpoint blockers and some do not, and to develop more effective combination immunotherapies.
Projects included in the collaboration will span laboratory research on patients' tumor samples and several early-stage clinical trials led by Johns Hopkins scientists at the Bloomberg-Kimmel Institute for Cancer Immunotherapy.